Xencor (XNCR) Income from Non-Controlling Interests (2023 - 2025)
Xencor (XNCR) posted quarterly Income from Non-Controlling Interests of -$97000.0 for Q2 2025, up 80.52% year-over-year from -$53733.0 in Q2 2024, and down 109.53% quarter-over-quarter from $1.0 million in Q1 2025.
Powered by 
Analysis
Xencor (XNCR) Income from Non-Controlling Interests (2023 - 2025) Analysis & Trends
Xencor (XNCR) has reported Income from Non-Controlling Interests for 3 consecutive years, with -$97000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Income from Non-Controlling Interests rose 80.52% year-over-year to -$97000.0; the TTM figure through Mar 2026 stood at -$97000.0 (down 114.12% YoY), while the FY2025 annual figure was -$214000.0, up 89.05% from the prior year.
- Income from Non-Controlling Interests eased to -$97000.0 in Q2 2025 per XNCR's latest filing, from $1.0 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.3 million in Q4 2024 and bottomed at -$1.4 million in Q1 2024.
- Historically, Income from Non-Controlling Interests has averaged -$145428.6 across 3 years, with a median of -$163000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests surged 910.43% — and 2025, when it soared 80.52%.
- Xencor's Income from Non-Controlling Interests stood at -$163000.0 in 2023, then soared by 910.43% to $1.3 million in 2024, then slumped by 107.34% to -$97000.0 in 2025.
- Business Quant data shows XNCR's Income from Non-Controlling Interests at -$97000.0 in Q2 2025, $1.0 million in Q1 2025, and $1.3 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -214,000.00 |
| Dec 31, 2024 | -647,000.00 |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -1.45 Mn |
| Mar 31, 2024 | -676,000.00 |
| Dec 31, 2023 | -163,000.00 |